Verona Pharma plc
VRNA
$105.27
$0.070.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 216.46M | 113.52M | 42.26M | 5.62M | -- |
| Total Other Revenue | 5.22M | 5.02M | 18.00K | -- | -- |
| Total Revenue | 221.67M | 118.54M | 42.28M | 5.62M | -- |
| Cost of Revenue | 10.75M | 5.99M | 2.58M | 543.00K | -- |
| Gross Profit | 210.93M | 112.55M | 39.70M | 5.08M | -- |
| SG&A Expenses | 221.52M | 198.43M | 149.75M | 119.64M | 97.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.52M | 253.27M | 193.31M | 156.93M | 128.87M |
| Operating Income | -53.85M | -134.73M | -151.03M | -151.30M | -128.87M |
| Income Before Tax | -72.94M | -154.65M | -163.13M | -151.76M | -123.69M |
| Income Tax Expenses | 8.24M | 9.30M | 10.29M | 1.97M | 1.76M |
| Earnings from Continuing Operations | -81.19 | -163.94 | -173.42 | -153.72 | -125.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.19M | -163.94M | -173.42M | -153.72M | -125.45M |
| EBIT | -53.85M | -134.73M | -151.03M | -151.30M | -128.87M |
| EBITDA | -52.74M | -133.64M | -149.97M | -150.30M | -127.97M |
| EPS Basic | -7.91 | -16.01 | -17.03 | -15.18 | -12.43 |
| Normalized Basic EPS | -0.55 | -1.15 | -1.22 | -1.14 | -0.93 |
| EPS Diluted | -8.17 | -16.32 | -17.34 | -15.49 | -12.75 |
| Normalized Diluted EPS | -0.56 | -1.15 | -1.22 | -1.14 | -0.93 |
| Average Basic Shares Outstanding | 334.97M | 330.35M | 326.14M | 323.50M | 321.79M |
| Average Diluted Shares Outstanding | 42.53M | 41.29M | 40.77M | 40.44M | 40.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |